Each clinical and preclinical studies have implicated glutamatergic system dysfunction while in the pathophysiology of mood Diseases. Particularly, immediate reductions in depressive symptoms are already noticed in response to subanesthetic doses with the glutamatergic modulator racemic (However success are mixed, some scientific studies have revea